Compare Nakanishi, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 10.82%
2
Company has very low debt and has enough cash to service the debt requirements
3
The company has declared Negative results for the last 3 consecutive quarters
4
Risky -
5
Majority shareholders : FIIs
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
7
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 198,327 Million (Small Cap)
26.00
NA
0.00%
-0.24
6.44%
1.66
Revenue and Profits:
Net Sales:
22,426 Million
(Quarterly Results - Dec 2025)
Net Profit:
-8,579 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
41.26%
0%
41.26%
6 Months
35.27%
0%
35.27%
1 Year
25.42%
0%
25.42%
2 Years
20.25%
0%
20.25%
3 Years
6.04%
0%
6.04%
4 Years
22.37%
0%
22.37%
5 Years
25.36%
0%
25.36%
Nakanishi, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.58%
EBIT Growth (5y)
10.12%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.52
Tax Ratio
49.70%
Dividend Payout Ratio
51.30%
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
23.45%
ROE (avg)
10.82%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
1.54
EV to EBIT
10.97
EV to EBITDA
7.68
EV to Capital Employed
1.69
EV to Sales
1.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.41%
ROE (Latest)
5.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
22,426.40
19,563.00
14.64%
Operating Profit (PBDIT) excl Other Income
5,113.10
4,396.00
16.31%
Interest
73.60
49.80
47.79%
Exceptional Items
-13,766.90
0.00
Consolidate Net Profit
-8,579.30
2,670.70
-421.24%
Operating Profit Margin (Excl OI)
158.20%
151.00%
0.72%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 14.64% vs -5.25% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -421.24% vs -13.01% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
81,179.10
77,041.40
5.37%
Operating Profit (PBDIT) excl Other Income
19,899.40
20,460.40
-2.74%
Interest
199.20
67.30
195.99%
Exceptional Items
-13,627.40
-3,464.50
-293.34%
Consolidate Net Profit
-2,398.20
8,578.80
-127.95%
Operating Profit Margin (Excl OI)
173.60%
189.50%
-1.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.37% vs 29.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -127.95% vs -62.38% in Dec 2024
About Nakanishi, Inc. 
Nakanishi, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






